Table 1.

Epidemiological data.

	Healthy controls	MS patients	NMOSD patients
Number of individuals	31	86	41
Age (median, IQR)	31 (27–34)	45 (34–52)	57 (45–64)
Sex (n female)	15 (48.4%)	53 (61.6%)	37 (90.2%)
Subtype (n)	–	RRMS: 63 (73.3%) SPMS: 15 (17.4%) PPMS: 5 (5.9%)	AQP4+: 23 (56.1%) MOG+: 7 (17.1%) Seronegative: 3 (7.3%) Unknown: 8 (19.5%)
Additional immune-mediated diseases (n)	Autoimmune thyroiditis (2), asthma bronchiale (1)	Autoimmune thyroiditis (10), asthma bronchiale (2), psoriasis (1), idiopathic myocarditis (1), celiac disease (1)	Autoimmune thyroiditis (3), myasthenia gravis (1), Sjögren syndrome (1), MCTD (1)
Immunosuppressive medication (n)	–	None: 24 (27.9%) Dimethyl fumarate: 15 (17.4%), glatiramer acetate: 14 (16.3%), interferon beta: 13 (15.1%), fingolimod: 7 (8.1%), teriflunomide: 5 (5.8%), methylprednisolone: 2 (2.3%), daclizumab: 2 (2.3%), rituximab: 1 (1.2%), ocrelizumab: 1 (1.2%), natalizumab 1 (1.2%)	Rituximab: 19 (46.3%) Azathioprine: 9 (22.0%) None: 6 (14.6%) Prednisolone: 3 (7.3%) Mycophenolate: 2 (4.9%) Glatiramer acetate: 1 (2.4%) Unknown: 1 (2.4%)

IQR interquartile range, RRMS relapse-remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive multiple sclerosis, AQP4+ aquaporin-4 antibody positive, MOG+ myelin oligodendrocyte glycoprotein antibody positive, MCTD mixed connective tissue disease).